Back to News
Market Impact: 0.3
AbbVie Secures EU Approval For RINVOQ In Children With Juvenile Arthritis
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The European Commission approved AbbVie's RINVOQ for active polyarticular juvenile idiopathic arthritis in children aged two years and older who have had an inadequate response or intolerance to one or more disease-modifying therapies. The approval expands RINVOQ's European pediatric treatment addressable market and supports AbbVie's immunology growth strategy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
ABBV0.70
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Bitcoin rebounds to $76,000, but $1.3 billion ETF exodus tests recovery